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Abstract In April 2015, the Spanish National Health System
(SNHS) developed a national strategic plan for the diagnosis,
treatment, and management of hepatitis C virus (HCV). Our
aim was to analyze the impact of this on human immunodefi-
ciency virus (HIV)-infected patients included in the
HERACLES cohort during the first 6 months of its implemen-
tation. The HERACLES cohort (NCT02511496) was set up in
March 2015 to evaluate the status and follow-up of chronic
HCV infection in patients co-infected with HIV in the south of





on behalf of the HERACLES cohort study team of the Grupo de
Estudio de Hepatitis Virales (HEPAVIR) of the Sociedad Andaluza
de Enfermedades Infecciosas (SAEI)
1 Unidad de Enfermedades Infecciosas, Hospital Universitario Reina
Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica
de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Avenida
Menéndez Pidal s/n, 14004 Córdoba, Spain
2 Unidad Clínica de Enfermedades Infecciosas, Microbiología y
Medicina Preventiva, Instituto de Biomedicina de Sevilla (IBiS),
Hospital Universitario Virgen del Rocío/CSIC/Universidad de
Sevilla, Seville, Spain
3 Unidad Clínica de Enfermedades Infecciosas, Hospital Regional
Universitario Carlos Haya, Málaga, Spain
4 Unidad Clínica de Enfermedades Infecciosas, Complejo Hospitalario
Universitario de Huelva, Huelva, Spain
5 Unidad Clínica de Enfermedades Infecciosas y Microbiología,
Hospital Regional Universitario Virgen de la Victoria, Málaga, Spain
6 Unidad Clínica de Enfermedades Infecciosas y Microbiología,
Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario de
Valme, Seville, Spain
7 Unidad Clínica de Enfermedades Infecciosas, Hospital Universitario
Puerto Real, Cádiz, Spain
8 Unidad Clínica de Enfermedades Infecciosas y Microbiología,
Hospital Universitario Virgen Macarena, Seville, Spain
9 Unidad Clínica de Enfermedades Infecciosas y Microbiología,
Hospital de Jerez, Jerez, Spain
10 Unidad Clínica de Enfermedades Infecciosas, Complejo Hospitalario
Torrecárdenas, Almería, Spain
11 Unidad Clínica de Enfermedades Infecciosas y Microbiología,
Hospital Universitario Virgen de las Nieves, Granada, Spain
12 Unidad Clínica de Enfermedades Infecciosas, Complejo Hospitalario
de Jaén, Jaén, Spain
13 Unidad Clínica de Enfermedades Infecciosas y Microbiología,
Hospital La Línea, AGS Campo de Gibraltad, Cádiz, Spain
14 Unidad deMedicina Interna, Hospital Costa del Sol, Marbella, Spain
15 Unidad Clínica de Enfermedades Infecciosas, Hospital Universitario
San Cecilio, Granada, Spain
16 Unidad Clínica de Enfermedades Infecciosas y Microbiología,
Hospital Puerta del Mar, Cádiz, Spain
17 Unidad de Medicina Tropical, Hospital de Poniente, El Ejido, Spain
Eur J Clin Microbiol Infect Dis (2017) 36:487–494
DOI 10.1007/s10096-016-2822-6
clinical events (death, liver decompensation, and liver fibrosis
progression) and rate of treatment implementation in this pop-
ulation. The study population comprised a total of 3474 HIV/
HCV co-infected patients. The distribution according to liver
fibrosis stage was: 1152 F0–F1 (33.2 %); 513 F2 (14.4 %);
641 F3 (18.2 %); 761 F4 (21.9 %); and 407 whose liver fibro-
sis was not measured (12.3%). During follow-up, 248 patients
progressed by at least one fibrosis stage [7.1 %; 95 % confi-
dence interval (CI): 6.3–8 %]. Among cirrhotic patients, 52
(6.8 %; 95 % CI: 5.2–8.9 %) developed hepatic decompensa-
tion. In the overall population, 50 patients died (1.4 %; 95 %
CI: 1.1–1.9%). Eight hundred and nineteen patients (23.56%)
initiated interferon (IFN)-free treatment during follow-up, of
which 47.8 % were cirrhotic. In our study, during 6 months of
follow-up, 23.56 % of HIV/HCV co-infected patients includ-
ed in our cohort received HCV treatment. However, we ob-
served a high incidence of negative short-term outcomes in
our population.
Introduction
The high efficacy and safety of direct-acting antiviral drugs
(DAAs) used for the treatment of hepatitis C virus (HCV) has
meant a significant improvement in cure rates [defined as
sustained virological response (SVR)] and, as a direct result,
an improved prognosis for this infectious disease [1–3].
Nevertheless, incorporating DAAs into patient care requires
implementing new and expensive resources, so limiting their
application in countries like Spain, which have universal free
healthcare systems. In this regard, in April 2015, the Spanish
National Health System (SNHS) developed a strategic plan
for diagnosing, treating, and managing HCV throughout
Spain [4]. This plan was approved in April 2015 and extended
across four strategic action lines, each with different objec-
tives and key action points. These lines included: (i) quantify-
ing the magnitude of this disease; (ii) defining the clinical
criteria for implementing appropriate treatment; (iii) establish-
ing coordination mechanisms to guarantee the proper imple-
mentation of the plan; and (iv) promoting knowledge about
the prevention, diagnosis, and treatment of HCV by fomenting
clinical and basic research [4]. To support these lines, key
clinical criteria for starting HCV therapy were determined,
as a result of which implementation of therapy was obligatory
for the majority of patients (Table 1). The development and
implementation of this plan, therefore, constitutes a major
advance in the eradication of HCV in Spain.
HCV patients co-infected with human immunodeficiency
virus (HIV) form an especially sensitive population. The use
of highly active antiretroviral therapy (HAART) led to liver
disease, mainly HCV infection, being identified as the main
cause of morbidity and mortality among HIV-infected patients
[5]. This effect is a direct consequence of higher and faster
liver fibrosis progression rates and lower sustained virological
response (SVR) rates, even using interferon (IFN)-free treat-
ments [6–8]. For these reasons, it is vitally important for this
population of patients to be part of a national strategy.
There are very few reports showing the impact of a national
program for treating chronic hepatitis C in HIV/HCV co-
infected patients. Here, therefore, we analyzed the impact on
HIV-infected patients included in the HERACLES cohort of
the Spanish national strategic plan for diagnosing, treating and
managing HCV infection during the first 6 months of its
implementation.
Methods
Study design and population
The HERACLES cohort, BStatus of Chronic Liver Disease in
Hepatitis C Virus (HCV) Patients Coinfected With Human
Immunodeficiency Virus (HIV) in Andalusia^, is a multicen-
ter prospective observational cohort study of HIV-infected
patients with active HCV co-infection (clinicaltrials.gov iden-
tification: NCT02511496). The cohort was set up in
March 2015, with the main objective of evaluating the current
status and follow-up of chronic HCV infection in patients co-
infected with HIV in Andalusia (southern Spain).
This cohort included HIV-infected patients with chronic
HCV infection in follow-up at 19 reference centers in
Andalusia for the care of HIV-infected patients. These 19 cen-
ters look after a population of 15,556 HIV-infected patients,
who represent 99.3 % of HIV-infected patients attending
Table 1 Criteria for treatment initiation and prioritization of the
Spanish national strategic plan for the diagnosis, treatment, and
management of HCV infection
Prioritization criteria for implementing HCV treatment
• All patients with liver fibrosis stages F4, F3, or F2
• Patients on the waiting list for liver transplant
• Patients with liver transplant, independent of stage of liver fibrosis
• Patients with failed treatment with Peg-IFN/RBV in combination with
boceprevir or telaprevir
• Patient who are recipients of non-liver transplants, independent of stage
of liver fibrosis
• Patients with extra-hepatic manifestations, independent of stage of liver
fibrosis
• Patients with stage F0–F2 liver fibrosis, in the following situations:
• Patients at risk of transmission
• Women wishing to become pregnant
HCV hepatitis C virus; F4 liver cirrhosis; F3 liver fibrosis stage 3; F2
liver fibrosis stage 2; F1 liver fibrosis stage 1;F0 absence of liver fibrosis;
Peg-IFN/RBV pegylated interferon plus ribavirin
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centers in the Andalusia healthcare system. These data were
obtained after an epidemiological inquiry in which all HIV-
infected patients attending the 21 reference centers of
Andalusia (n = 15,663) were tested [9]. HIV-infected patients
were included in the cohort if they matched the following
inclusion criteria: (i) active chronic HCV infection (defined
as detectable HCV RNA in serum) and (ii) not receiving treat-
ment for HCVat inclusion.
Variable collection and definition
At inclusion in the cohort (March–April 2015), the demo-
graphic, clinical, and virological characteristics of participants
were collected and recorded. These were considered the base-
line characteristics, and included: age, gender, risk for HCV
infection, use of HAART, CD4+ cell count (cells/mL), plasma
HIV viral load (copies/mL), acquired immune deficiency syn-
drome (AIDS)-defining criteria, HCV plasma viral load (IU/
mL), HCV genotype/subtype, liver fibrosis stage, Child–
Turcotte–Pugh (CTP) classification (A, B, or C), and history
of HCV therapy.
Bi-annual follow-up of patients included in the cohort was
planned. Variables collected and recorded at each follow-up
visit included: liver fibrosis stage, use of DAA-based anti-
HCV therapy during follow-up, achieving SVR, presence
and type of liver decompensation, inclusion on the waiting list
for transplant, liver transplant, death, and cause of death.
Variables for this report were collected in August–September
2015 (6-month follow-up).
Liver fibrosis staging was performed by liver biopsy
(following the METAVIR fibrosis score) and/or liver tran-
sient elastography (FibroScan; Echosens, Paris, France).
Classification of liver fibrosis staging was by histological
analysis or liver stiffness measurement (LSM) score as
follows: (i) F0–F1 METAVIR fibrosis score or LSM <7.2
kPa; (ii) F2 METAVIR fibrosis score or LSM 7.2–8.9 kPa;
(iii) F3 METAVIR fibrosis score or LSM 9–14.5; and (iv)
F4 METAVIR fibrosis score or LSM ≥14.6 kPa. Liver fi-
brosis stage was measured at baseline and at each subse-
quent visit in order to determine the liver fibrosis stage at
each visit and, hence, the degree of liver fibrosis progres-
sion. A liver fibrosis stage of at least one stage higher with
respect to the baseline was considered liver fibrosis pro-
gression. Liver stiffness measurement was planned for
each study visit.
In cirrhotic patients, liver decompensation was consid-
ered as the following hepatic events: portal hypertensive
gastrointestinal bleeding (PHGB), ascites, hepatorenal syn-
drome (HRS), spontaneous bacterial peritonitis (SBP), he-
patic encephalopathy (HE), and hepatocarcinoma (HCC).
Health status or cause of death was collected at each visit.
Cause of death was classified as AIDS-related, liver-related,
or other cause. Exitus due to other causes was specified in the
data collection.
HIVand HCV viral loads were obtained using reverse tran-
scription polymerase chain reaction (RT-PCR) (Cobas
TaqMan; Roche Diagnostic Systems Inc., Pleasanton, CA,
USA). Undetectable HIV viral load was defined as an HIV
RNA viral load of less than 50 copies per mL.
Statistical analysis
Analysis of the population included in the study was de-
scriptive. Characteristics of patients (qualitative variables)
were reported as the number of cases (percentages).
Numerical variables were reported as medians (interquar-
tile range). Otherwise, the population description was di-
vided into patients who were receiving HCV treatment
during follow-up and those who were not. For patients
receiving treatment during follow-up, a comparative anal-
ysis according to HCV genotype, liver fibrosis stage, and
previous experience of HCV therapy was performed in
order to identify variables with an impact on the clinical
decision to initiate therapy. Those variables were compared
using the Chi-square test.
An analysis evaluating the rate of liver fibrosis progression
was performed. Liver fibrosis progression was considered as
an increase of at least one liver fibrosis stage with respect to
the baseline. Patients with liver fibrosis stage F4 at baseline
were censored from analysis. The mortality rate was calculat-
ed as the overall number of deaths in the total population.
Otherwise, mortality rates were determined for patients with
cirrhosis (F4) and F0–F3 patients, specifying cause of death.
Ethics
This study was conducted according to the principles of
Good Clinical Practice (Ministry of Health, Royal Decree
223/2004 of 6 February) and the Declaration of Helsinki.
The study did not require informed consent because the
patients were not directly interviewed and completely
anonymous information was collected from existing re-
cords, ensuring the protection of personal data in accor-
dance with Law 15/1999 of 13 December on Personal
Data Protection. The study coordinator presented the study
protocol (protocol code: FIBICO-0015/01017-2015) to the
Coordinating Ethics Committee for Biomedical Research
in Andalusia for evaluation and obtained approval (240-
2819-05/15). Those responsible for the provision of health
services where the study occurred were given a copy of the
protocol and documents evidencing approval by the Ethics
Committee in accordance with the procedures and legal
requirements.
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Results
Baseline population and characteristics
A total of 3474 HIV/HCV co-infected patients were included
in the cohort and formed the study population. This implies a
prevalence of active HCV infection in the south of Spain of
22.4 %. The distribution of patients according to HCV geno-
type was: 1944 HCV genotype 1 (56.07 %), 38 HCV geno-
type 2 (1.01 %), 559 HCV genotype 3 (16.08 %), 736 HCV
genotype 4 (21.2 %), three HCV genotype 6 (0.08 %), and
194 whose HCV genotype was not available (5.56 %).
Among patients infected by HCV genotype 1, 862 were ge-
notype 1a (44.2 %), 461 genotype 1b (23.6 %), 49 HCV
genotype 1ab (2.6 %), and in 572 patients, the HCV subtype
was not determined (29.6 %). When patients were sorted ac-
cording to liver fibrosis stage, 1152 patients were F0–F1
(33.2 %), 513 were F2 (14.4 %), 641 were F3 (18.2 %), 761
were F4 (21.9 %), and in 407 patients, liver fibrosis was not
staged (12.3 %). When patients were grouped according to
previous experience of HCV therapy, 2453 were naïve
(70.6 %), 898 did not respond to pegylated interferon plus
ribavirin (Peg-IFN/RBV) (25.8 %), and 123 did not respond
to Peg-IFN/RBV in combination with boceprevir or telaprevir
(3.6 %).
Follow-up: clinical events
After 6 months of follow-up, liver fibrosis stage had
progressed by at least one stage in 248 patients [7.1 %;
95 % confidence interval (CI): 6.3–8 %]. Of these, 108 F0–
F1 patients progressed to F2–F4 (9.3 %; 95 % CI: 7.8–
11.2 %), 80 F2 patients progressed to F3–F4 (15.6 %; 95 %
CI: 12.7–19 %), and 59 F3 patients progressed to F4 (9.2 %;
95 % CI: 7.2–11.7 %).
Among 761 patients with cirrhosis, 52 (6.8 %; 95 % CI:
5.2–8.9 %) developed hepatic decompensation during the
6 months of follow-up, which included ascites in 28
(53.8 %) patients, HCC in 14 (26.9 %), PHGB in 6
(11.5 %), HE in 3 (5.7 %), and SBP in 1 (1.9 %). The cumu-
lative incidence of HCC in cirrhotic patients during the 6
months of follow-up was 1.8 % (95 % CI: 1.1–3.1 %).
Fifty patients died during follow-up. The mortality rate was
1.4 % (95 % CI: 1.1–1.9 %). Causes of death according to
liver fibrosis stage are summarized in Table 2.
Follow-up: treatment implementation
Eight hundred and nineteen patients (23.56 %) initiated treat-
ment for HCV infection in the first 6 months of the implemen-
tation of a national strategy for the diagnosis, treatment, and
management of HCV in Spain, or a rate of 4.55 treatment
implementations per day. 2654 patients, therefore, were not
treated. The main baseline characteristics of treated and non-
treated patients are shown in Table 3. Of the 52 patients in the
decompensated liver stage of F4, 50 initiated therapy against
HCV infection. The two patients who did not initiate therapy
died before starting treatment due to complications of liver
decompensation.
The proportion of treated patients by liver fibrosis stage,
HCV genotype, and previous experience of HCV therapy are
shown in Fig. 1. A total of 90 F0–F1 patients initiated treat-
ment during the follow-up. Of these, 49 (54.4 %) experienced
treatment failure with a DAA + Peg-IFN/RBV regimen, 27
(28.8 %) showed extra-hepatic manifestations or another co-
morbidity, 13 (14.4 %) were treated for epidemiological rea-
sons, and 1 (2.4 %) was a renal transplant patient.
Discussion
We report the first results of the impact of the Spanish national
strategic plan for the diagnosis, treatment, and management of
HCV on HIV/HCV co-infected patients in the HERACLES
cohort. During the first 6 months of follow-up, a high propor-
tion (819, 23.56 %) of HIV/HCV co-infected patients includ-
ed in the cohort initiated DAA-based anti-HCV therapy.
However, despite this, there was a high incidence of negative
short-term outcomes among the HIV/HCV patients in our
cohort; in this regard, 248 (7.1 %; 95 % CI: 6.3–8 %) patients
progressed by at least one stage of liver fibrosis, 52 cirrhotic
patients (6.8 %; 95 % CI: 5.2–8.9 %) developed hepatic de-
compensation, and 50 patients (1.4 %; 95 % CI: 1.1–1.9 %)
died.
Liver fibrosis stage was the main factor involved in the
decision to initiate anti-HCV therapy. Cirrhotic patients con-
stitute the principal sensitive HCV population group due to
the short-term risk of liver decompensation and liver-related
death [10, 11]. The benefit of successful anti-HCV treatment
in this subset of patients, in the sense that it significantly re-
duces both morbidity and mortality, is generally recognized
[3, 12]. The general use of direct-acting antiviral agents is,
therefore, a priority for these patients because this is the target
population that derives the most benefit in the short term [13].
In our cohort, 761 patients (24.8 %) showed liver cirrhosis and
392 (51.5 %) of these received anti-HCV therapy during the 6
months of follow-up. By contrast, 52 (6.8%) cirrhotic patients
suffered liver decompensation during follow-up and 15
(1.9 %) died. On the other hand, the number of active HCV
infection patients in our cohort with no or mild liver fibrosis
(F0–F2) starting treatment for hepatitis C was low. Stage F0–
F1 fibrosis was detected in 1152 (33.1 %) patients, and 90
(7.8 %) of these received anti-HCV therapy. This proportion
was significantly lower than for stage F2 (15.3 %), stage F3
(34.6 %), and cirrhotic patients (51.5 %), most likely due to
prioritization policies in the prescription of IFN-free, direct-
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Table 3 Characteristics of
treated and non-treated patients Characteristics Treated (n = 819) Non-treated (N = 2654) p-Value
Age (years), median (IQR) 50 (47–53) 48 (45–52) 0.001
Gender, no. (%)
Male 683 (83.3) 2437 (91.7) 0.256
Female 136 (16.7) 217 (8.3)
Risk group for HCV infection, no. (%)
IDU 710 (86.7) 2318 (87.3) 0.876
Sexual 97 (11.8) 321 (12.1)
Blood-derived 12 (1.5) 15 (0.6)
HAART, no. (%)
Receiving 810 (98.9) 2550 (96) 0.214
Non-receiving 9 (1.1) 104 (4)
CD4+ total count (cells/mL), median (IQR) 527 (344–760) 487 (305–702) 0.001
HCV genotype, no. (%)
1 508 (62.02) 1436 (54.2) 0.72
1a 253 (49.8) 609 (42.2)
1b 116 (22.8) 345 (23.9)
1a/b 16 (3.2) 33 (2.3)
NG 123 (24.2) 449 (31.9)
2 10 (1.2) 28 (0.9)
3 131 (15.9) 428 (16.1)
4 169 (20.6) 567 (21.3)
6 1 (0.28) 2 (0.2)
NG 0 194 (7.3)
Liver fibrosis stage, no. (%)
F0–F1 90 (10.9) 1062 (40) <0.001
F2 79 (9.6) 434 (16.3)
F3 222 (27.1) 419 (15.7)
F4 392 (47.8) 369 (13.9)
Not staged 36 (4.6) 371 (14.1)
Previous experience of HCV therapy, no. (%)
Naïve 366 (44.6) 2087 (78.6) 0.014
Failure of Peg-IFN/RBV 373 (45.5) 525 (19.7)
Failure of BOC- or TPV-based regimen 80 (9.9) 43 (1.7)
IQR interquartile range; IDU injecting drug user;HAART highly active antiretroviral therapy;NG non-genotyped;
BOC boceprevir; TPV telaprevir
Table 2 Causes of death during
follow-up, according to liver
fibrosis stage
Overall (n = 3474) F0–F3 (n = 2713) F4 (n = 761) p-Value
Death (n = 50) 50 (1.4%) 34 (1.2 %) 16 (2.1%) 0.082
Causes n =50 n = 34 n = 16
Liver-related 15 (30) 4 (11.7 %) 11 (68.7) <0.001
Non-AIDS malignancies 10 (19.2) 6 (17.6 %) 4 (25) 0.588
Systemic bacterial infection 7 (13.4) 7 (20.6 %) 0 0.054
Cardiovascular event 6 (9.6) 6 (17.6 %) 0 0.116
Abuse of toxic substances 4 (7.6) 3 (8.8 %) 1 (6.3) 0.792
AIDS-related 3 (5.7) 3 (8.8 %) 0 0.389
Gastrointestinal bleeding* 2 (3.8) 2 (5.9 %) 0 0.771
End-stage renal disease 2 (3.8) 2 (5.9 %) 0 0.771
Suicide 2 (3.8) 1 (3.1 %) 0 0.66
*Gastrointestinal bleeding does not include bleeding from esophageal varices
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acting antiviral agent-based therapies for HCV in the Spanish
national plan. In addition, HIV/HCV co-infected patients rep-
resent a highly sensitive population due to the high rate of
liver fibrosis progression compared to HCV monoinfected
patients [14, 15]. Indeed, in our cohort, 8 % of F0–F2 patients
progressed to the F3–F4 stage of liver fibrosis during just
6 months of follow-up. This observation may be added to
the list of reasons in favor of prioritizing anti-HCV treatment,
regardless of fibrosis stage, in patients with HIV/HCV co-
infection.
Chronic HCV infection increases the mortality rate for
hepatic and extra-hepatic diseases [16]. In our cohort, 52
(1.5 %) patients died during the 6 months of follow-up.
Liver-related deaths accounted for 30 % of all causes of
death in our study. The course of chronic HCV is acceler-
ated in HIV/HCV-co-infected patients, with more rapid
liver fibrosis progression and more frequent hepatic de-
compensation events compared to HCV monoinfected pa-
tients [7, 8, 17]. Consequently, HCV-related liver compli-
cations have emerged as a significant cause of mortality
among HIV/HCV co-infected patients. HAART is an im-
portant factor in slowing liver fibrosis progression, al-
though its use is not sufficient to reduce the rates of end-
stage liver disease to those of HCV monoinfected patients
[7]. For this reason, HIV co-infected patients are consid-
ered a priority for receiving anti-HCV therapy regardless
of liver fibrosis stage, so as to reduce the rate of hepatic
decompensation. As expected in a cohort of HIV-infected
patients containing a high proportion of subjects with sup-
pressed HIV viral loads due to HAART, mortality due to
AIDS-related events was low, accounting for 5.7 % of
causes of death. In contrast, non-AIDS/non-liver-related
conditions constituted the main cause of death in our co-
hort. Cardiovascular diseases and non-AIDS/non-liver ma-
lignancies have been related to both HCV and HIV infec-
tion. In our cohort, non-AIDS/non-liver malignancies com-
prised 64.3 % of all causes of death. The incidence of non-
AIDS-defining malignancies is elevated in chronic HIV
infection [18, 19]. In addition, some evidence has sug-
gested that HCV may be associated with the development
of malignancies such as B-cell non-Hodgkin lymphoma,
intrahepatic cholangiocarcinoma, and the incidence of pan-
creatic cancer [20]. Genomic and/or HCV replicative se-
quences have been detected in extra-hepatic localizations
and it has been speculated that HCV may promote persis-
tent inflammation in extra-hepatic organs and induce can-
cerous transformations [20]. Finally, in our cohort, five
patients died due to cardiovascular disease; in other words,
9.6 % of all deaths. This is not striking, because cardiovas-
cular disease is a major cause of morbidity and mortality in
HIV-infected patients, accounting for at least 10 % of
deaths [21, 22], and the evidence in favor of HCV infection
promoting major risk factors for cardiovascular disease is
compelling [23].
The prevalence of HCV active infection among HIV-
infected patients has decreased in recent years. The preva-
lence of chronic HCV infection in Spain in 2002 was 54 %
[24], decreasing to 34 % in 2009 [25], then to 22.1 % (402
out of 1882) in 2015 [26]. The baseline prevalence
(March 2015) of chronic HCV infection in our cohort
was similar, at 22.4 %. The progressive decrease of active
HCV infection in our setting is due to at least three factors.
Firstly, to changes in the route of HIV transmission. The
decline of injecting drug users (IDUs) as the predominant
route for transmission of HIV infection is probably the
Fig. 1 Distribution of patients receiving hepatitis C virus (HCV) therapy,
according to HCV genotype (a), liver fibrosis stage (b), and previous
experience of HCV therapy (c), with respect to the global population
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main factor governing the steady decrease in active HCV
infection in Spain [27]. The prevalence of IDUs among
Spanish patients newly infected with HIV decreased from
67.3 % in 1997 to 14.5 % in 2006, with a parallel reduction
in the rate of HCV co-infection (from 73.8 % in 1997 to
19.8 % in 2006) in these patients [27]. Secondly, the re-
duction in active HCV infection is due to the high mortality
among HIV/HCV co-infected patients. I t is well
established that individuals with HIV/HCV co-infection
have significantly higher morbidity and mortality rates
compared to individuals with HIV monoinfection [5, 28,
29]. As a result, liver-related complications currently rep-
resent one of the leading causes of death in the HIV-
infected population. This particular aspect may have con-
tributed to the progressive decrease in active HCV infec-
tion among HIV-infected patients in our area. Finally, the
third reason is the use of highly effective anti-HCV thera-
py. The great majority of clinical trials evaluating the effi-
cacy of DAAs have demonstrated high SVR rates in both
HIV/HCV co-infected and HCV-infected patients [1, 2]. In
our cohort, during the first 6 months of implementation of
this national strategic plan for HCV, 819 (23.5 %) of the
HIV/active HCV-infected patients received DAA-based
anti-HCV therapy. It is assumed that, in the coming
months, the widespread use of anti-HCV therapy will in-
crease HCV cure rates and, hence, reduce active HCV in-
fection rates among HIV/HCV co-infected individuals.
Our study presents several limitations that should be noted.
Firstly, in the initiation phase of the study, not all DAA regi-
mens had been approved in Spain and, so, the impact of this
national strategic plan for the diagnosis, treatment, and man-
agement of HCVmay be limited in this respect. Secondly, due
to the fact that only HIV/HCV co-infected patients were in-
cluded in our cohort, it was not possible to compare the impact
of implementation on HCV monoinfected patients. Thirdly,
liver fibrosis stage could not be established in 12.3 % of pa-
tients included in the study. These patients represent a special
population for whom the national strategic plan cannot be
implemented because of the absence of priority markers.
Finally, although we mentioned that the majority (99.3 %) of
HIV/HCV co-infected patients being followed in our area
were included in our cohort, we do not know what proportion
of patients have no access to clinical care.
In conclusion, during the first 6 months, 1 in 4 HIV/HCV
co-infected patients, mainly with advanced liver fibrosis, were
treated in the HERACLES cohort as a result of the Spanish
national strategic plan for the diagnosis, treatment, and man-
agement of HCV. However, despite this apparent good news,
the high incidence of negative short-term outcomes observed
in our cohort makes it indispensable to continue providing
extra resources to increase the rate of HIV/HCV co-infected
patients receiving anti-HCV therapy, in order to improve the
prognosis for this highly sensitive population.
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